IGHE and cancer: Despite the loss of sialic acid residues, we showed that glyco-engineered IgE produced and purified via this pipeline retained recognition of immune cells expressing both cognate IgE Fc receptors, FcεRI and CD23, as well as of cancer cells expressing the target antigen, CSPG4 [Figure 4].